🇺🇸 intrathecal chemotherapy in United States

17 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 17

Most-reported reactions

1. Drug Interaction — 4 reports (23.53%)
2. Mucosal Inflammation — 4 reports (23.53%)
3. Drug Toxicity — 2 reports (11.76%)
4. Blood Lactate Dehydrogenase Abnormal — 1 report (5.88%)
5. Blood Lactate Dehydrogenase Increased — 1 report (5.88%)
6. Blood Ph Increased — 1 report (5.88%)
7. Candida Osteomyelitis — 1 report (5.88%)
8. Drug Clearance Decreased — 1 report (5.88%)
9. Drug Level Increased — 1 report (5.88%)
10. Inhibitory Drug Interaction — 1 report (5.88%)

Source database →

Frequently asked questions

Is intrathecal chemotherapy approved in United States?

intrathecal chemotherapy does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for intrathecal chemotherapy in United States?

Princess Maxima Center for Pediatric Oncology is the originator. The local marketing authorisation holder may differ — check the official source linked above.